Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 7/2003

01-07-2003 | Original Article

Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effects

Authors: Thierry Lesimple, Annick Moisan, André Carsin, Isabelle Ollivier, Mireille Mousseau, Bernard Meunier, Claudine Leberre, Brigitte Collet, Véronique Quillien, Bernard Drenou, Claudia Lefeuvre-Plesse, Jacqueline Chevrant-Breton, Louis Toujas

Published in: Cancer Immunology, Immunotherapy | Issue 7/2003

Login to get access

Abstract

Patients' autologous macrophages (AM) were used as antigen-presenting cells (APC) in a vaccination protocol against malignant melanoma. AM were administered by various routes, including intralymphatic, since these cells did not express CCR7, a molecule required for APC migration to lymph nodes. Seven HLA-A2 patients with metastatic melanoma—two classified as M1 and five as M3—were included in the study. AM were produced from leukapheresis-separated mononuclear cells by 7-day culture with granulocyte-macrophage colony-stimulating factor. After separation by elutriation, AM were frozen in aliquots and subsequently thawed at monthly intervals, exposed to MAGE-3(271–279) peptide and injected subcutaneously into lymph nodes or into one peripheral lymph vessel. Intradermal tests were performed before and after treatment to determine peptide reactivity. No acute toxicity was observed following injection. One M1 patient had a 7-mm induration intradermal reaction response and was stabilized for 64 weeks. The M3 patients did not show any immunological or clinical response. In 11 patients, the biodistribution of 111In-labeled AM was investigated. There was no clear evidence that AM injected intradermally or subcutaneously left the site of injection. After injection into a lymph vessel of the foot region, scintigraphs showed five to ten popliteal and inguinocrural lymph nodes. This appeared to be the most efficient way to administer rapidly and safely large amounts of peptide-loaded APC into lymph nodes.
Literature
1.
Mukherji B, Chakraborty NG, Yamasaki S, et al (1995) Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci U S A 92:8078PubMed
2.
Nestle FO, Alijagic S, Gilliet M, et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328PubMed
3.
Morse MA, Lyerly HK, Li Y (1999) The role of IL-13 in the generation of dendritic cells in vitro. J Immunother 22:506PubMed
4.
Toujas L, Delcros JG, Diez E, et al (1997) Human monocyte-derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class-restricted exogenous peptides. Immunology 91:635PubMed
5.
Lesimple T, Moisan A, Toujas L (1998) Autologous macrophages and antitumour cell therapy. Res Immunol 149:663CrossRefPubMed
6.
Lappin MB, Weiss JM, Delattre V, et al (1999) Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology 98:181PubMed
7.
Hermans IF, Ritchie DS, Yang J, et al (2000) CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol 164:3095PubMed
8.
Balch CM, Buzaid AC, Atkins MB, et al (2000) A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 88:1484CrossRefPubMed
9.
Quillien V, Raoul JL, Heresbach D, et al (1997) Expression of MAGE genes in esophageal squamous cell carcinoma. Anticancer Res 17:387PubMed
10.
Lesimple T, Moisan A, Guillé F, et al (2000) Treatment of metastatic renal carcinoma with activated autologous macrophages and granulocyte-macrophage colony-stimulating factor. J Immunother 23:675CrossRef
11.
Musson RA, Henson PM (1979) Humoral and formed elements of blood modulate the response of peripheral blood monocytes. I. Plasma and serum inhibit and platelets enhance monocyte adherence. J Immunol 122:2026PubMed
12.
Quillien V, Moisan A, Lesimple T, et al (2001) Biodistribution of 111-indium-labelled macrophages infused intravenously in patients with renal carcinoma. Cancer Immunol Immunother 50:477CrossRefPubMed
13.
Marienhagen J, Hennemann B, Andreesen R, Eilles C (1995) 111In-oxine labelling of tumour-cytotoxic macrophages generated in vitro from circulating blood monocytes: an in vitro evaluation. Nucl Med Commun 16:357PubMed
14.
Boon T, Coulie P, Karanikas V, et al (2001) Therapeutic vaccination with tumor antigens recognized by cytolytic T lymphocytes. Melanoma Res 11:538
15.
Brasseur F, Rimoldi D, Lienard D, et al (1995) Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63:375PubMed
16.
Van der Bruggen P, Bastin J, Gajewski T, et al (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038
17.
Tjandrawan T, Martin DM, Maeurer MJ, et al (1998) Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. J Immunother 21:149
18.
Kawashima I, Hudson SJ, Tsai V, et al (1998) The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 59:1CrossRef
19.
Kanaoka S, Yamasaki S, Okino T, et al (1999) Induction of human leukocyte antigen (HLA)-A2-restricted and MAGE-3-gene-derived peptide-specific cytolytic T lymphocytes using cultured dendritic cells from an HLA-A2 esophageal cancer patient. J Surg Oncol 71:16PubMed
20.
Takaki T, Hiraki A, Uenaka A, et al (1998) Variable expression on lung cancer cell lines of HLA-A2-binding MAGE-3 peptide recognized by cytotoxic T lymphocytes. Int J Oncol 12:1103
21.
Chaux P, Luiten R, Demotte N, et al (1999) Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol 163:2928PubMed
22.
Labarriere N, Pandolfino MC, Raingeard D, et al (1998) Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes. Int J Cancer 78:209CrossRefPubMed
23.
Valmori D, Gileadi U, Servis C, et al (1999) Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J Exp Med 189:895PubMed
24.
Gajewski TF, Fallarino F, Ashikari A, Sherman M (2001) Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin. Clin Cancer Res 7 [3 Suppl]:895s
25.
Schuler-Thurner B, Dieckmann D, Keikavoussi P, et al (2000) Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol 165:3492PubMed
26.
Eggert AA, Schreurs MW, Boerman OC, et al (1999) Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 59:3340PubMed
27.
Barratt-Boyes SM, Watkins SC, Finn OJ (1997) In vivo migration of dendritic cells differentiated in vitro: a chimpanzee model. J Immunol 158:4543PubMed
28.
Barratt-Boyes SM, Watkins SC, Finn OJ (1997) Migration of cultured chimpanzee dendritic cells following intravenous and subcutaneous injection. Adv Exp Med Biol 417:71PubMed
29.
Morse MA, Coleman RE, Akabani G, et al (1999) Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59:56PubMed
30.
Thomas R, Chambers M, Boytar R, et al (1999) Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy. J Melanoma Res 5:474
31.
Sallusto F, Lanzavecchia A (2000) Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev 177:134PubMed
32.
Mackensen A, Krause T, Blum U, et al (1999) Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother 48:118CrossRefPubMed
33.
Lambert LA, Gibson GR, Maloney M, et al (2001) Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 61:641PubMed
Metadata
Title
Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effects
Authors
Thierry Lesimple
Annick Moisan
André Carsin
Isabelle Ollivier
Mireille Mousseau
Bernard Meunier
Claudine Leberre
Brigitte Collet
Véronique Quillien
Bernard Drenou
Claudia Lefeuvre-Plesse
Jacqueline Chevrant-Breton
Louis Toujas
Publication date
01-07-2003
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 7/2003
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-003-0390-y

Other articles of this Issue 7/2003

Cancer Immunology, Immunotherapy 7/2003 Go to the issue

Original Article

Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells

Original Article

Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation

Original Article

Adenocarcinoma cells exposed in vitro to Navelbine or Taxol increase Ep-CAM expression through a novel mechanism

Original Article

Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses

Original Article

Transient exposure of dendritic cells to maturation stimuli is sufficient to induce complete phenotypic maturation while preserving their capacity to respond to subsequent restimulation

Editorial

Editorial statement from R.W. Baldwin
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits